{
    "Trade/Device Name(s)": [
        "ARCHITECT\u00ae CA 19-9\u2122MxR Assay",
        "ARCHITECT\u00ae CA 19-9\u2122MxR Calibrator Kit",
        "ARCHITECT\u00ae CA 19-9\u2122MxR Control Kit"
    ],
    "Submitter Information": "Fujirebio Diagnostics, Inc.",
    "510(k) Number": "K052000",
    "Predicate Device Reference 510(k) Number(s)": [
        "K020566"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NIG",
        "JIT",
        "JJX"
    ],
    "Summary Letter Date": "July 21, 2005",
    "Summary Letter Received Date": "July 27, 2005",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "CA 19-9 (1116-NS-19-9 reactive determinants)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Sodium tube",
        "Lithium tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT System",
        "ARCHITECT i System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent Microparticle Immunoassay (CMIA)"
    ],
    "Methodologies": [
        "Immunoassay",
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ARCHITECT CA 19-9xR chemiluminescent microparticle immunoassay for quantitative measurement of CA 19-9 in serum or plasma to aid in the management of pancreatic cancer patients",
    "Indications for Use Summary": "Quantitative determination of CA 19-9 in serum or plasma as an aid in management of pancreatic cancer patients, used on the ARCHITECT System in conjunction with other clinical methods",
    "fda_folder": "Immunology"
}